CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation

NCT02893189 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

CD19+ Malignancies: Relapse Post-allogeneic Transplant

Interventions

GENETIC: Infusion of modified CAR19 T-cells (4G7-CARD T-cells)

Sponsor

University College, London